August 24, 2011 By

Diabetes Medications, One Old and One New, Run into Trouble

A potential new treatment for type 2 diabetes, dapagliflozin, recently failed to gain approval from the FDA. What makes this rejection noteworthy is that the new medication works by a completely new mechanism causing the kidney to excrete sugar from the blood into the urine. Reasons for the rejection were the increased risk of bladde [...]

May 16, 2011 By

Are New Diabetes Medications Worth the Money?

(I don’t think so, and here’s why.) The FDA just announced its approval of linagliptin (Tradjenta), a new diabetes medication developed by Eli Lilly and Company and Boehringer Inglheim. Linagliptin is the third drug to be approved in the class of medications commonly known as gliptins (scientifically known as dipeptidyl peptidase-4 (DPP-4) inhibitors) which block [...]

January 18, 2010 By

New Diabetes Treatment Guidelines Flawed

New Diabetes Treatment Guidelines Lack Credibility: Recently the American Academy of Clinical Endocrinologists issued new treatment guidelines for treating Type 2 Diabetes. Complex medical guidelines are often referred to as a treatment algorithm. One of the stated goals of the AACE algorithm is to focus primarily on the theoretical ability of the diabetic medications to [...]

June 16, 2009 By

Unreasonable Standards by the FDA for New Diabetes Drug Approval?

This post is the third in a series under the title: 2009. Another Troubled Year for Endocrinologists. This year the FDA has instituted new standards for diabetes drugs coming up for approval. These new standards require that each new drug prior to approval must demonstrate the lack of any negative impact on cardiovascular (heart and [...]

October 19, 2007 By

Two More Diabetes Drugs in Trouble This Week

Two of the newest diabetes treatments suffered major set-backs this week. Endocrinologists across the U.S. received a notice today that Exubera, the inhaled form of insulin, would soon become unavailable. This is because Pfizer, the pharmaceutical giant which has sole rights for marketing Exubera has decided to end its role in selling this drug. This [...]

© 1998-2012 Metabolink, Inc. All rights reserved. Please read the Terms of Service and our Privacy Policy. Please send your feedback, comments and suggestions as well as marketing inquiries to marketing@metabolism.com. * From time to time advertising on our web pages provided by third parties may appear to offer hormone therapy without a prescription. It is beyond our control that such advertising is displayed. Metabolism.com deplores this type of advertising and is doing whatever possible to eliminate it. If you have a complaint we encourage you to address it to the company associated with the ad. Receiving treatment with growth hormone or testosterone without a prescription from a licensed professional is illegal, as is receiving treatment with these hormones for the sole purpose of enhancing athletic performance. Physicians who prescribe growth hormone or testosterone without performing a proper examination and history, and without provision for appropriate follow-up care, are breaking the law. We at metabolism.com continue to support an open and complete discussion of the use of these hormones for medical therapy.